Empowered Funds’s Spero Therapeutics SPRO Stock Holding History

Empowered Funds’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$77.1K	Buy	+63,741	New	+$86.5K	﹤0.01%	2442

Other funds holding SPRO

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Empowered Funds's SPRO Position: Q3 2026 in Review

Empowered Funds opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 63,741 shares worth $77.1K. The stake represents ﹤0.01% of the portfolio and ranks #2442 among its holdings.

44 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

Empowered Funds held 63,741 shares of Spero Therapeutics worth $77.1K as of Q3 2026.
Spero Therapeutics was a new Empowered Funds position in Q3 2026.
Spero Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2442 holding.
44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.